Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

JCO precision oncology·2026
Same author

Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.

Journal of neuro-oncology·2026
Same author

Pan-tumor validation of FoundationOne<sup>®</sup>CDx as a companion diagnostic for <i>RET</i> fusions as a predictor of response to selpercatinib.

Frontiers in oncology·2026
Same author

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer.

JCO precision oncology·2026
Same author

Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study.

JCO precision oncology·2026
Same author

Genomics of <i>MTAP</i> Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms.

JCO precision oncology·2026

Related Experiment Video

Updated: Jan 7, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from

Rachel B Keller-Evans1, Zoe Fleischmann1, Smruthy Sivakumar1

  • 1Foundation Medicine, Inc., Boston, Massachusetts.

The Journal of Molecular Diagnostics : JMD
|January 4, 2026
PubMed
Summary

Pathogenic POLE mutations (pPOLE) cause DNA replication errors and ultramutation, predicting immunotherapy response. A new model identified 29 pPOLE across >490,000 samples, aiding cancer classification and treatment.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Related Experiment Videos

Last Updated: Jan 7, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Area of Science:

  • Genomics
  • Cancer Biology
  • Molecular Diagnostics

Background:

  • Pathogenic POLE mutations (pPOLE) impair DNA mismatch repair, leading to somatic ultramutation.
  • Previous classification of pPOLE relied heavily on exonuclease domain location.
  • Ultramutation resulting from pPOLE is linked to immunotherapy response.

Purpose of the Study:

  • To develop and apply a comprehensive POLE-specific phenotypic classification model.
  • To identify novel pathogenic POLE mutations (pPOLE) beyond recurrent alleles.
  • To characterize the clinical and molecular landscape of tumors with pPOLE.

Main Methods:

  • Developed a POLE phenotypic classification model using TMB, mutational signatures, germline frequency, and co-mutation data.
  • Applied the model to over 490,000 tumor samples.
  • Analyzed co-mutations with HR pathway genes in endometrial and colorectal cancers.

Main Results:

  • Identified 29 predicted pPOLE, including 16 novel variants, in 748 tumors (0.2%).
  • pPOLE tumors exhibited ultramutation (median TMB 186.3 mut/Mb) across various cancer types.
  • Concurrent pPOLE and MSI-High showed synergistic TMB increase (median 325.6 mut/Mb).
  • Identified passenger HR mutations unlikely to predict DNA repair deficiency therapy response.

Conclusions:

  • A refined POLE classification model expands the identification of pPOLE.
  • pPOLE are associated with ultramutation and impact immunotherapy response.
  • Understanding pPOLE aids in clinical management and treatment guideline integration.